Poolbeg Pharma plc (AIM: POLB) has received Clinical Trial Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency for its POLB 001 TOPICAL trial, marking a key regulatory milestone
RNS Hotlist with Zak Mir: HVO, BMV, POLB, WPHO, MTEC, HAMA, TAM, ORCP, ASTR & THX
hVIVO plc (HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announced its audited results for the year ended 31 December 2025. Revenue of
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Share Talk Weekly Stock Market News Review, Sunday 5th April 2026
The United Kingdom faces a critical petrol shortage at the pumps during the Easter weekend, with retail experts warning of potential diesel shortages within weeks. The confluence of heightened demand, geopolitical
Poolbeg Pharma (AIM: POLB) Significant milestone for Poolbeg’s IP portfolio
Grant of first POLB 001 cancer immunotherapy-induced CRS patent Significant milestone for Poolbeg’s global intellectual property portfolio
Share Talk Weekly Stock Market News Review, Sunday 15th March 2026
The UK stock market ended another volatile week on a weaker footing, marking its second consecutive weekly decline. The FTSE 100 finished Friday down 44 points, or 0.43%, closing at
Poolbeg Pharma (AIM: POLB) Appointment of Dr Adrian Kilcoyne to SAB
Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
Share Talk Weekly Stock Market News Review, Sunday 1st February 2026
The week closed with the UK equities edging higher. In London, the FTSE 100 rose 0.5% to finish at 10,224 points, while the FTSE 250 was little changed at 23,253.
RNS Hotlist with Zak Mir: HUI, HAMA, GENF, RHR, IHC, LEND, CDL, POLB, DEBS, EQIP & ALK
Hydrogen Utopia International PLC (HUI), a pioneering leader in converting non-recyclable mixed waste plastics, tyres, and hazardous waste materials into hydrogen and carbon-free fuels, announced the signing of a Memorandum of
Poolbeg Pharma (AIM: POLB) POLB 001 LPS Challenge Trial Paper Published
Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
Share Talk Weekly Stock Market News Review, Sunday 11th January 2026
The FTSE 100 ended the week at a new record high. London’s benchmark index advanced 0.8% to close at 10,124.60 points, with gains led by Glencore. Precious metals edged higher after data pointed
10 Companies to Watch in 2026
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.